FDA Approves First PARP Inhibitor for Early BRCA+ Breast Cancer FDA Approves First PARP Inhibitor for Early BRCA+ Breast Cancer

Overall survival results showing a 32% reduction in mortality with olaparib vs placebo will be presented at an upcoming EMSO virtual plenary session.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news